Literature DB >> 22171208

Sodium oxybate and sleep apnea: a clinical case.

Sarah Hartley1, Maria-Antonia Quera-Salva, Mourad Machou.   

Abstract

Sodium oxybate (GHB, Xyrem, Jazz Pharmaceuticals) is used to treat cataplexy in patients with narcolepsy. We report the case of a middle aged, normo-ponderal narcoleptic woman without risk factors who developed reversible sleep apnea and objective sleepiness when treated by sodium oxybate, with an apnea-hypopnea index (AHI) of 19.7 on sodium oxybate and AHI 4.8 without treatment. Despite a subjective improvement in vigilance, mean sleep latency on MWT decreased from 21 minutes to 8 minutes on sodium oxybate.

Entities:  

Keywords:  Narcolepsy with cataplexy; periodic leg movements; sleep apnea; sodium oxybate

Mesh：

Substances：

Year:  2011        PMID： 22171208      PMCID： PMC3227715          DOI： 10.5664/jcsm.1480

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


  6 in total

1.  Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: two case reports.

Authors:  M Seeck-Hirschner; P C Baier; A von Freier; J Aldenhoff; R Göder
Journal:  Sleep Med       Date:  2008-01-28       Impact factor: 3.492

2.  Sodium oxybate and breathing.

Authors:  Juan Jose Ortega-Albas; Roberto López-Bernabé; Jose Ramón Diaz; Angel Luis Serrano
Journal:  Sleep Breath       Date:  2009-11-27       Impact factor: 2.816

3.  Three deaths associated with use of Xyrem.

Authors:  Deborah L Zvosec; Stephen W Smith; Brad J Hall
Journal:  Sleep Med       Date:  2009-03-09       Impact factor: 3.492

4.  A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.

Authors:  Charles F P George; Neil Feldman; Neil Inhaber; Teresa L Steininger; Susanna M Grzeschik; Chinglin Lai; Yanping Zheng
Journal:  Sleep Med       Date:  2009-11-07       Impact factor: 3.492

Review 5.  Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing.

Authors:  Neil T Feldman
Journal:  Sleep Breath       Date:  2009-07-23       Impact factor: 2.816

6.  A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome.

Authors:  Charles F P George; Neil Feldman; Yanping Zheng; Teresa L Steininger; Susanna M Grzeschik; Chinglin Lai; Neil Inhaber
Journal:  Sleep Breath       Date:  2010-01-18       Impact factor: 2.816
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.